# Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

> **NCT04263298** · PHASE3 · RECRUITING · sponsor: **Herui Yao** · enrollment: 210 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Capecitabine Oral Product

## Key facts

- **NCT ID:** NCT04263298
- **Lead sponsor:** Herui Yao
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-05-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2030-05-01
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2022-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04263298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04263298, "Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04263298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*